The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab (GUAVA)

Royal North Shore Hospital

Status: Not yet enrolling

Conditions: Glioblastoma; Glioblastoma Multiforme (GBM)

Treatments: Diagnostic Test: PSMA PET/CT scan

Study type: Observational

Funder types: Other

Identifiers

NCT07052877

GUAVA

Details and patient eligibility

About

This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.

Enrollment: 20 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• > 18 year of age
• ECOG 0-2
• Able to provide informed consent for the study
• Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour
• Confirmed glioblastoma IDH1/2 wildtype (WHO2021)
• For bevacizumab treatment as per treating physician
• Able to comply with trial requirements

Exclusion criteria

• No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment)
• Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope
• Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging
• Does not fulfill PBS requirements for bevacizumab
• Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study

Trial design

20 participants in 1 patient group

Patients with glioblastoma receiving Bevacizumab as part of their standard of care

Treatment:

Diagnostic Test: PSMA PET/CT scan